-
tisotumab vedotin Examples:
Sofituzumab vedotin Polatuzumab vedotin (RG7596)
Enfortumab vedotin Pinatuzumab vedotin Lifastuzumab vedotin Brentuximab vedotin Glembatumumab...
-
Tisotumab vedotin, sold
under the
brand name Tivdak, is an antibody-drug
conjugate used to
treat cervical cancer. It is a
combination of tisotumab, a...
-
Brentuximab vedotin, sold
under the
brand name Adcetris, is an antibody-drug
conjugate medication used to
treat relapsed or
refractory Hodgkin lymphoma...
-
Enfortumab vedotin, sold
under the
brand name Padcev, is an antibody-drug
conjugate used for the
treatment of
urothelial cancer. It is a nectin-4-directed...
-
Polatuzumab vedotin, sold
under the
brand name Polivy, is a CD79b-directed antibody-drug
conjugate medication used for the
treatment of
diffuse large...
-
antitumor activity. The company's
flagship product Adcetris (brentuximab
vedotin) is
commercially available for four
indications in more than 65 countries...
-
Glembatumumab vedotin (also
known as CDX-011 and CR011-vcMMAE) is an antibody-drug
conjugate (ADC) that
targets cancer cells expressing transmembrane...
-
Indusatumab vedotin (MLN-0264) is an antibody-drug
conjugate that is
under development for the
treatment of
pancreatic cancer and
other gastrointestinal...
-
Sofituzumab vedotin (INN;
development code DMUC5754A) is a
monoclonal antibody designed for the
treatment of
ovarian cancer. This drug was
developed by...
-
Telisotuzumab vedotin is a
monoclonal antibody developed by
AbbVie for non-small cell lung cancer. Camidge, D. Ross; Barlesi, Fabrice; Goldman, Jonathan...
